Abstract
The expression and clinical significance of transforming growth factor beta1 (TGF-beta1) and matrix metalloproteinase-2 (MMP2) in human renal clear cell carcinoma (RCCC) were investigated. The intensity of TGF-beta1 and MMP2 expression in RCCC kidneys was significantly higher than that in normal kidneys. Expression of TGF-beta1 and MMP2 in RCCC tissues was positively correlated with pathological grade and clinical stage. There was also a significant correlation between TGF-beta1 and Msshese analyses indicate that upregulation of TGF-beta1 and MMP2 expression may occur during the progression of RCCC. Thus, TGF-beta1 and MMP2 may be useful molecular markers for evaluating prognosis in RCCC patients.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Biomarkers, Tumor / genetics
-
Biomarkers, Tumor / metabolism
-
Carcinoma, Renal Cell / genetics
-
Carcinoma, Renal Cell / metabolism*
-
Carcinoma, Renal Cell / mortality
-
Carcinoma, Renal Cell / pathology
-
China / epidemiology
-
Disease Progression
-
Female
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Immunohistochemistry
-
Kidney / pathology
-
Kidney / surgery
-
Kidney Neoplasms / genetics
-
Kidney Neoplasms / metabolism*
-
Kidney Neoplasms / mortality
-
Kidney Neoplasms / pathology
-
Male
-
Matrix Metalloproteinase 2 / genetics
-
Matrix Metalloproteinase 2 / metabolism*
-
Middle Aged
-
Neoplasm Staging
-
Prognosis
-
RNA, Messenger / metabolism
-
Survival Rate
-
Transforming Growth Factor beta1 / genetics
-
Transforming Growth Factor beta1 / metabolism*
-
Young Adult
Substances
-
Biomarkers, Tumor
-
RNA, Messenger
-
Transforming Growth Factor beta1
-
MMP2 protein, human
-
Matrix Metalloproteinase 2